Search Results

You are looking at 101 - 110 of 178 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Stephen B. Edge

-inferiority phase 3 trial . Lancet 2010 ; 376 : 91 – 102 . 32 Hughes KS Schnaper LA Berry D . Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer . N Engl J Med 2004 ; 351 : 971 – 977

Full access

Renee W. Pinsky and Mark A. Helvie

density changes risk. Tamoxifen has been proven to decrease breast cancer risk and cause decreased breast density in many women. 35 Making the mammogram less dense may also diminish the effect of masking. The antiestrogen effect of tamoxifen in the breast

Full access

Oxana Palesh, Arianna Aldridge-Gerry, Ayhan Ulusakarya, Elisabet Ortiz-Tudela, Lucile Capuron, and Pasquale F. Innominato

relationship between sleep and age in patients and survivors diagnosed with breast cancer. Cancer Treatments Lorizio et al 33 reported that women with higher levels of endoxifen, the most active metabolite of tamoxifen, were more likely to experience

Full access

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021

Featured Updates to the NCCN Guidelines

William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Jennifer Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer . JAMA 2006 ; 295 : 1658 – 1667 . 10.1001/jama.295.14.1658 16609087 4. Paik S , Shak S , Tang G , A multigene assay to predict recurrence of tamoxifen

Full access

Hiram S. Cody III and Kimberly J. Van Zee

: Findings from the National Surgical Adjuvant Breast and Bowel Project B-17 . J Clin Oncol 1998 ; 16 : 441 – 452 . 19 Fisher B Dignam J Wolmark N . Tamoxifen in the treatment of intraductal breast cancer: National Surgical Adjuvant Breast and

Full access

Michael B. Streiff

drug therapy in women with stage II breast cancer . N Engl J Med 1988 ; 318 : 404 – 407 . 12. Pritchard KI Paterson AH Paul NA . Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of

Full access

Kilian E. Salerno

. Hughes KS Schnaper LA Bellon JR . Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343 . J Clin Oncol 2013 ; 31 : 2382 – 2387 . 6. Kunkler IH

Full access

Amy Cyr

-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study . J Clin Oncol 2010 ; 28 : 1829 – 1834 . 5. Grotenhuis BA Vrijland WW Klem TM . Radiofrequency ablation for early

Full access

Sundar Jagannath

postmenopausal women with breast cancer in community and academic centers before and after the availability of ATAC (Adjuvant Tamoxifen, Arimidex or Combination) study [abstract] . J Clin Oncol 2007 ; 25 ( Suppl 1 ): Abstract 6621 . 13. McKibbin T

Full access

Mary B. Daly, Tuya Pal, Michael P. Berry, Saundra S. Buys, Patricia Dickson, Susan M. Domchek, Ahmed Elkhanany, Susan Friedman, Michael Goggins, Mollie L. Hutton, CGC, Beth Y. Karlan, Seema Khan, Catherine Klein, Wendy Kohlmann, CGC, Allison W. Kurian, Christine Laronga, Jennifer K. Litton, Julie S. Mak, LCGC, Carolyn S. Menendez, Sofia D. Merajver, Barbara S. Norquist, Kenneth Offit, Holly J. Pederson, Gwen Reiser, CGC, Leigha Senter-Jamieson, CGC, Kristen Mahoney Shannon, Rebecca Shatsky, Kala Visvanathan, Jeffrey N. Weitzel, Myra J. Wick, Kari B. Wisinski, Matthew B. Yurgelun, Susan D. Darlow, and Mary A. Dwyer

has been suggested that the increased risk for endometrial cancer observed in some carriers of BRCA1/2 pathogenic or likely pathogenic variants may be due to the use of tamoxifen therapy by these women rather than the presence of a gene mutation. 118